Journal
NATURE NEUROSCIENCE
Volume 22, Issue 5, Pages 719-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41593-019-0372-9
Keywords
-
Categories
Funding
- National Institute on Aging (NIA)
- National Institute on Drug Abuse
- NIA [P30-AG0-28383]
- NATIONAL INSTITUTE ON AGING [ZIAAG000735, ZIAAG000393, ZIAAG000518] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Neuritic plaques, a pathological hallmark in Alzheimer's disease (AD) brains, comprise extracellular aggregates of amyloid-beta (A beta) peptide and degenerating neurites that accumulate autolysosomes. We found that, in the brains of patients with AD and in AD mouse models, A beta plaque-associated Olig2- and NG2-expressing oligodendrocyte progenitor cells (OPCs), but not astrocytes, microglia, or oligodendrocytes, exhibit a senescence-like phenotype characterized by the upregulation of p21/CDKN1A, p16/INK4/CDKN2A proteins, and senescence-associated beta-galactosidase activity. Molecular interrogation of the A beta plaque environment revealed elevated levels of transcripts encoding proteins involved in OPC function, replicative senescence, and inflammation. Direct exposure of cultured OPCs to aggregating A beta triggered cell senescence. Senolytic treatment of AD mice selectively removed senescent cells from the plaque environment, reduced neuroinflammation, lessened A beta load, and ameliorated cognitive deficits. Our findings suggest a role for A beta-induced OPC cell senescence in neuroinflammation and cognitive deficits in AD, and a potential therapeutic benefit of senolytic treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available